Allinaire Therapeutics, founded in 2016 by BioMotiv with licensed technology from Indiana University, focuses on developing novel therapeutics for cardiopulmonary diseases, including Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Arterial Hypertension (PAH). The core mission of Allinaire is to innovate and provide disease-modifying treatments that significantly improve patient outcomes. Their primary product in development is a humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibody.
Notable affiliations include BioMotiv, now managed by Advent Life Sciences, which provides strategic support and investment. Key achievements include the progression of their EMAP II monoclonal antibodies as a potential treatment for PAH. Allinaire's impact lies in its potential to transform the treatment landscape for severe pulmonary diseases, offering hope for improved quality of life for patients suffering from these conditions.
